Skip to content
    Omega Funds logo

    Omega Funds

    Boston, Massachusetts, United StatesFounded 2004
    omegafunds.comLinkedIn
    Biotech & Life SciencesHealthcare

    Omega Funds is a global healthcare venture capital firm that creates and invests in life sciences companies targeting the world's most urgent medical needs, across therapeutic areas including oncology, immunology, rare diseases, and precision medicine. Founded in 2004 and headquartered in Boston, the firm invests from early venture rounds through public company financing.

    43% of their portfolio is in Biotech & Life Sciences. Deal activity increased 57% year-over-year (11 deals in the last 12 months). Average disclosed round size is $100.6M (across 97 rounds with reported amounts).

    Find people at Omega Funds on Goldilocks AI

    Portfolio

    91

    Fund Size

    $647M

    Top Stage

    Series B

    Last 12 Mo

    7

    Team

    CN

    Claudio Nessi

    Managing Director

    FD

    Francesco Draetta

    Managing Director

    OS

    Otello Stampacchia

    Managing Director

    BD

    Bernard Davitian

    Investment Professionals

    KK

    Kurt Kongtong-Gallagher

    Investment Professionals

    MD

    Michelle Doig

    Investment Professionals

    NH

    Noelle Hutchins

    Investment Professionals

    SB

    Saoussen Ben Halima

    Investment Professionals

    VO

    Vincent Ossipow

    Investment Professionals

    BJ

    Brent Jiang

    Operations

    DC

    Deirdre Cunnane

    Management

    DK

    Denise Kiley

    Administration

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    112 investments
    CompanyRoundAmountDate
    Third Arc Bio logoThird Arc BioSeries A$52MFeb 2026
    Alveus Therapeutics logoAlveus TherapeuticsSeries A$160MJan 2026
    Spiro Medical logoSpiro MedicalSeries A$67MJan 2026
    Protego logoProtegoSeries B$130MDec 2025
    Artios Pharma logoArtios PharmaSeries D$115MNov 2025
    AArtiosSeries D$115MNov 2025
    NRG Therapeutics logoNRG TherapeuticsSeries B$50MSep 2025
    BBridgeBio Oncology TherapeuticsUnknown$261MAug 2025
    ArtBio logoArtBioSeries B$132MJul 2025
    Ousia Pharma logoOusia PharmaUnknown—May 2025
    EEvolytesSeed—Apr 2025
    Callio Therapeutics logoCallio TherapeuticsSeries A$187MMar 2025
    Windward Bio logoWindward BioSeries A$200MJan 2025
    AAviceda TherapeuticsSeries C—Jan 2025
    BBridgeBio Oncology TherapeuticsUnknown$260MJan 2025
    Treble logoTrebleSeries A—Sep 2024
    Language I/O logoLanguage I/OSeed$5MJul 2024
    CatalYm logoCatalYmSeries D$150MJul 2024
    BBridgeBio Oncology Therapeutics (BBOT)Growth$200MMay 2024
    Alumis logoAlumisSeries C$259MMar 2024
    ArtBio logoArtBioSeries A$90MDec 2023
    Lightforce Orthodontics logoLightforce OrthodonticsSeries D$80MAug 2023
    Chroma Medicine logoChroma MedicineSeries B$135MMar 2023
    Forward Networks logoForward NetworksSeries D$50MJan 2023
    SoniVie logoSoniVieUnknown$60MJan 2023
    Page 1 of 5

    Top Co-Investors

    Cormorant Asset Management17 shared
    Surveyor Capital13 shared
    OrbiMed13 shared
    Frazier Healthcare Partners13 shared
    Atlas Venture12 shared
    RA Capital Management12 shared
    Redmile Group12 shared
    Sofinnova Partners11 shared
    Longitude Capital11 shared
    Andera Partners11 shared
    The Invus Group, LLC11 shared
    Foresite Capital10 shared
    Casdin Capital9 shared
    Wellington Management9 shared
    Avidity Partners9 shared
    Pfizer Ventures9 shared
    Polaris Partners9 shared
    GV8 shared
    Forbion8 shared
    Alexandria Venture Investments7 shared

    Last updated: 7 September 2026